FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT	OF CHANGI	ES IN BENEF	ICIAL OW	NERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Saad M	Iark E	Reporting Person*	(Middle)	3.	2. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM] 3. Date of Earliest Transaction (Month/Day/Year) 02/27/2024				(Che	ck all applic Director	able)	erson(s) to Isse 10% Ov Other (s below)	vner		
C/O AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 22ND FLOOR				4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(Street) NEW Y	ORK N	Y	10007	 R	ule '	10h5-1	(c) :	Transac	tion Indi	cation		Person			
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			. Transactio ate Month/Day/Y	Execution Date,		Date,	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			5. Amour Securities Beneficia Owned F	s Fo ally (D ollowing (I)	orm: Direct) or Indirect (Instr. 4)	7. Nature of ndirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion Date Executity Or Exercise (Month/Day/Year) if		3A. Deemed Execution Date if any (Month/Day/Ye	Code	Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$84	02/27/2024		A		1,519 ⁽¹⁾		02/27/2024	02/26/2034	Common Stock	1,519	\$0.00	1,519	D	

Explanation of Responses:

1. Represents 1,519 options elected to be received in lieu of cash compensation earned in 2023. All of such options are immediately exercisable.

/s/ Herriot Tabuteau, M.D., **Attorney in Fact**

** Signature of Reporting Person

02/29/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).